Neither Ozempic nor Wegovy are listed on the PBS to treat obesity. When Wegovy becomes available, users will need to pay the full price. Or should the government subsidise it?
Academic rigor, journalistic flair
Articles on Semaglutide
Displaying 1 - 20 of 24 articles
The animal studies are promising but early research in humans show mixed results. Here’s what we know so far.
Some women who use drugs like Ozempic have reported unexpected pregnancies. What’s going on?
Does weight come back when you stop taking drugs like Ozempic? Are these medications simply another (expensive) form of yo-yo dieting? Here’s what we know so far.
We don’t tell people taking statins to treat high cholesterol or drugs to manage high blood pressure they’re cheating or taking the easy way out. Nor should we when people take drugs like Ozempic.
In Australia, Ozempic is only approved to treat diabetes but doctors are prescribing it ‘off label’ for weight loss. Compounding pharmacies have also been making their own versions to meet demand.
Ozempic generated A$21 billion of sales in 2023 alone. So how was it developed? And how are its new competitors, Mounjaro and Zepbound, different?
Early on we heard a lot about the potential benefits of drugs like Ozempic. Now we’re hearing more about the risks. But what does the latest evidence say?
When people stopped taking one of the new weight-loss jabs they regained around 60% of their lost weight.
People who are obese, as well as those who are overweight and have weight-related issues, may soon be able to ask their doctor for a prescription.
In trials, Mounjaro was shown to be more effective than Ozempic in managing type 2 diabetes.
The Conversation has been following the trials and tribulations of semaglutide (Wegovy) as it made its way from lizard venom to blockbuster drug.
Weight-loss jabs might help with certain heart conditions, but their benefit is being overstated.
The messaging around Ozempic being a miracle cure is not only a lie, it has kicked up a new level of fatphobia.
Ongoing shortages of the drug have been reported in the UK, Australi and Ireland.
Overreliance on BMI as a measure of weight and health has deepened inequities and led to inaccuracies and overgeneralizations.
As the use of Ozempic, a drug for diabetes, slams into the mainstream as a weight-loss method, will the drug’s use impact our concept of fatness? And how does fatness intersect with race and class?
Some pharmacies are selling ‘generic’ semaglutide online, despite the drug still being under patent protection.
Obesity is said to cost the NHS an estimated £6 billion a year.
The much-discussed weight-loss jab may be good for treating Britain’s biggest killer: dementia. Trials are underway.
Top contributors
-
Associate Professor of Metabolic Medicine, University of Surrey
-
Associate Professor of the School of Pharmacy, University of Sydney
-
Assistant Professor, Critical Disability Studies, Carleton University
-
General Practitioner, PhD Candidate, Bond University
-
Laureate Professor in Nutrition and Dietetics, University of Newcastle
-
Adjunct Senior Lecturer, Nutrition, Dietetics & Food Innovation - School of Health Sciences, UNSW Sydney
-
Karin Hammarberg is a Friend of The Conversation.
Senior Research Fellow, Global and Women's Health, School of Public Health & Preventive Medicine, Monash University
-
Professor of Psychobiology, University of Leeds
-
Lecturer, Southern Cross University
-
Postdoctoral Researcher, School of Public Health, University College Cork
-
Assistant Professor of Medicine, School of Medicine, University of Washington
-
Emeritus Professor of Reproductive and Periconceptual Medicine, The Robinson Research Institute, University of Adelaide
-
DPhil Candidate, Alzheimer's, University of Oxford
-
Associate Professor in Pharmacy Practice, University of Bradford
-
Lecturer Pharmacy Practice, University of Sydney
